Literature DB >> 10543278

Myofibroblasts and S-100 protein positive cells in idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial pneumonia.

T Yoshinouchi1, Y Ohtsuki, R Ueda, S Sato, N Ueda.   

Abstract

The aim of this study was to investigate whether idiopathic pulmonary fibrosis (IPF) can be distinguished from rheumatoid arthritis (RA)-associated interstitial pneumonia (RA-IP) by means of quantitatively assessing myofibroblasts and S-100 protein positive dendritic cells. Seven patients with IPF and twelve with RA, in whom the pathological findings were consistent with usual interstitial pneumonia (UIP) were studied. Antibodies to vimentin, alpha-smooth muscle actin (alpha-SMA) and S-100 protein were used for immunohistochemical studies performed using the streptavidin/biotin/peroxidase complex method, applied to dewaxed sections from each case. In fibrosis of RA-IP, appearance of both vimentin- and alpha-SMA-positive cells, namely myofibroblasts, was widely observed, together with the pathological patterns of honeycombing, UIP and bronchiolitis obliterans-organizing pneumonia (BOOP). Fibrosis, in cases of chronic IPF, was found to be characterized mainly by vimentin-positive but alpha-SMA-negative fibroblasts. Pulmonary tissues from RA-IP patients especially when associated with a BOOP pattern, contained many cells positive for S-100 protein. However, such cells were generally hard to find in cases of IPF. These findings suggests that idiopathic pulmonary fibrosis and rheumatoid arthritis-associated interstitial pneumonia can be differentiated from each other, to some extent, based on the appearance of myofibroblasts and the presence of S-100-positive dendritic cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10543278     DOI: 10.1034/j.1399-3003.1999.14c16.x

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Lower-lobe shrinkage relative to total lung volume in collagen vascular diseases.

Authors:  M Watanabe; T Igishi; N Burioka; J Kurai; Y Fukuoka; K Kato; A Yamasaki; Y Hasegawa; R Okazaki; E Shimizu
Journal:  Radiol Med       Date:  2010-06-23       Impact factor: 3.469

2.  Detection of antivimentin antibody in sera of patients with idiopathic pulmonary fibrosis and non-specific interstitial pneumonia.

Authors:  Y Yang; J Fujita; S Bandoh; Y Ohtsuki; I Yamadori; T Yoshinouchi; T Ishida
Journal:  Clin Exp Immunol       Date:  2002-04       Impact factor: 4.330

Review 3.  Bronchus-associated lymphoid tissue (BALT) structure and function.

Authors:  Troy D Randall
Journal:  Adv Immunol       Date:  2010       Impact factor: 3.543

4.  Triptolide protects against TGF-β1-induced pulmonary fibrosis by regulating FAK/calpain signaling.

Authors:  Pingheng Zhang; Jian Liu; Ruikai Zong
Journal:  Exp Ther Med       Date:  2019-10-25       Impact factor: 2.447

Review 5.  Role of antifibrotics in the management of idiopathic inflammatory myopathy associated interstitial lung disease.

Authors:  Erin M Wilfong; Rohit Aggarwal
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-12-09       Impact factor: 3.625

Review 6.  Bronchoalveolar lavage and lung biopsy in connective tissue diseases, to do or not to do?

Authors:  Sara Tomassetti; Thomas V Colby; Athol U Wells; Venerino Poletti; Ulrich Costabel; Marco Matucci-Cerinic
Journal:  Ther Adv Musculoskelet Dis       Date:  2021-12-08       Impact factor: 5.346

7.  Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.

Authors:  Sho Sendo; Jun Saegusa; Hirotaka Yamada; Keisuke Nishimura; Akio Morinobu
Journal:  Arthritis Res Ther       Date:  2019-08-06       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.